News and Announcements
Idol Co-Founder Presents their opportunity to Australia at Wholesale Investor events
- Published June 18, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS
- Idol offer 20% token bonus and 10% bounty
- With a Private Sale Target of USD$20 million
- Co-founder, Adam Li, presents live at WI and BMYG collaborative event in Sydney
The month of June has been a successful month for the Idol team. Co-founder Adam Li has travelled Australia with his team, presenting the idol opportunity live at Wholesale Investors events.
Last week on June the 12th co-founder Adam Li participated in Wholesale Investor and BMYG’s collaborative event in Sydney. Li presented the opportunity of Idol to the BMYG-WI investor filled room. View the presentation below.
Idol Entertainment are currently offering a 20% token bonus and a 10% bounty to private sale investors.
Private Sale Target: USD$20 million
Please proceed to ‘request offer’ to find out more information for our KYC process (contributions made by investors during the private sale will be collected manually).
About Idol Entertainment
Idol is the world’s fan-driven entertainment community, focusing on the monetization and commercialization of celebrities for fans. Built upon the Ethereum network, Idol utilizes the properties of blockchain technology and the flexibility of smart contracts to provide innovative solutions for the major key players within the entertainment industry: fans, celebrities, and entertainment companies.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
